Taken together, our findings suggest that PKCε alteration could play a role in ALS pathophysiology, and PKCε agonism by Bryostatin-1 may represent a potential neuroprotective strategy against motor neuronal degeneration in a specific subgroup of sporadic ALS patients. Here, PRKCE is linked to amyotrophic lateral sclerosis.